Athenex, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Warrants

Rhea-AI Summary

Athenex (Nasdaq: ATNX) announced plans for an underwritten public offering of its common stock, pre-funded warrants, and accompanying warrants, subject to market conditions. The offering is managed by SVB Securities and aims to raise capital for the company's ongoing development of novel cancer therapies. Key details about the offering will be disclosed in a preliminary prospectus supplement. The company warns that market conditions may affect the final terms and completion of the offering.

Positive

• Athenex aims to raise funds for the development of its cancer therapies through the offering.
• Offering managed by SVB Securities may enhance investor confidence.

Negative

• Market conditions may impact the successful completion of the offering.
• Potential dilution of shares may concern current investors.

BUFFALO, N.Y., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc. (“Athenex”) (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock, or pre-funded warrants to purchase common stock in lieu of common stock to certain investors, and accompanying warrants to purchase shares of its common stock, in an underwritten public offering. All of the shares of common stock, warrants and pre-funded warrants are being offered by Athenex.

SVB Securities is acting as sole book-running manager for the offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

The offering is being made only by means of a previously filed effective registration statement (including a base prospectus) and a preliminary prospectus supplement. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering, when available, may be obtained from: SVB Securities LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@svbsecurities.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there by any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Athenex, Inc. 
Founded in 2003, Athenex, Inc. is a global clinical-stage biopharmaceutical company dedicated to becoming a leader in the discovery, development, and commercialization of next generation cell therapy drugs for the treatment of cancer. In pursuit of this mission, Athenex leverages years of experience in research and development, clinical trials, regulatory standards, and manufacturing. The Company’s current clinical pipeline is derived mainly from the following core technologies: (1) Cell therapy, based on NKT cells and (2) Orascovery, based on a P-glycoprotein inhibitor. Athenex’s employees worldwide are dedicated to improving the lives of cancer patients by creating more active, accessible, and tolerable treatments.

Forward Looking Statements
Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. These forward-looking statements are typically identified by terms such as “anticipate,” “continue,” “could,” “expect,” “intend,” “may,” “plan,” “potential,” “strategy” “will,” and similar expressions. While Athenex believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Athenex’s filings with the SEC), many of which are beyond Athenex’s control and subject to change. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Risks and uncertainties include: changes as a result of market conditions or for other reasons; the risk that the offering will not be consummated; the exercise of the warrants to be issued in the offering; the impact of general economic, health, industrial or political conditions in the United States or internationally; and other risks and uncertainties identified in Athenex’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 and other subsequent disclosure documents filed with the SEC. All information provided in this release is as of the date hereof, and we assume no obligation and do not intend to update these forward-looking statements, except as required by law.

Contacts
Daniel Lang, MD
Athenex, Inc.
Email: danlang@athenex.com

Caileigh Dougherty
Athenex, Inc.
Email: cdougherty@athenex.com

FAQ

What type of securities is Athenex offering in the August 2022 press release?

Athenex is offering common stock, pre-funded warrants to purchase common stock, and accompanying warrants in an underwritten public offering.

Who is managing Athenex's public offering?

SVB Securities is acting as the sole book-running manager for the offering.

How might Athenex's stock be affected by this offering?

The offering could lead to potential dilution of shares, impacting current shareholders.

When is Athenex planning to complete the public offering?

The completion of the offering is subject to market conditions, with no specific date provided.